About
Arintra builds a GenAI-native autonomous medical coding and revenue-assurance platform for health systems and physician groups. Its differentiation is combining clinical AI and specialty-specific coding expertise with direct EHR integrations, explainable outputs, and workflows covering coding, documentation improvement, and denials prevention.
Market
Arintra competes in healthcare IT and revenue-cycle management, specifically the AI-powered autonomous medical-coding market serving health systems and physician groups. It positions itself as a GenAI-native platform and differentiates through deep, bi-directional EHR integration, direct-to-billing coding, minimal IT or workflow disruption, and explainable coding decisions rather than bolt-on tools; Arintra reports outcomes including 5%+ revenue uplift and 43%+ fewer denials.
Arintra primarily targets large health systems and physician groups that want to automate medical coding, improve revenue integrity, reduce denials, and accelerate reimbursement. Revenue-cycle and coding teams are the main operational stakeholders, while physicians benefit from automation that does not disrupt their documentation workflows.
At a Glance
Problem
Arintra addresses the financial and operational cost of delayed and inaccurate medical coding, which the company says costs U.S. hospitals and clinics $125 billion annually. The pain arises when clinical documentation is translated slowly or incorrectly into billable codes, creating undercoding, claim denials, delayed reimbursement, and avoidable manual work. The central use case is turning a completed patient chart into an accurate insurance claim without waiting for a human coder to review it.
Product / Service
Arintra is a clinical-AI platform for autonomous medical coding. It converts patient charts into insurance claims, generating E/M levels, CPT, ICD-10, HCC, and HCPCS codes with applicable modifiers and units. The platform integrates bi-directionally with major EHRs such as Epic, Athena, and Cerner, allowing charts to flow directly from the EHR into a billing-ready claim. Arintra reports 96% coding accuracy with zero human intervention, and says its automation has reduced undercoding by 11% and coding-related denials by 43%.
The company is expanding beyond coding into broader revenue assurance, including clinical documentation improvement and denial prevention. Its documentation-improvement capability gives health systems and physician groups visibility into documentation gaps affecting revenue and denials, from the organizational level to individual providers.
Market
Arintra competes in healthcare revenue-cycle software, specifically the medical-coding automation and AI-enabled revenue-assurance categories. It is positioned as a B2B SaaS product for hospitals, health systems, clinics, and large physician groups. The gathered sources do not name specific competitors, so the most supportable comparison is to incumbent and emerging medical-coding, clinical-documentation-improvement, and denial-management vendors rather than to a particular company.
The evidence indicates meaningful commercial traction rather than an unvalidated concept: Arintra is listed as an active Winter 2022 Y Combinator company, reports partnerships with health systems and large physician groups, and says those deployments achieved 100% success. The company was founded in 2020, is reported to have 50 employees, raised a $21 million Series A, and launched documentation-improvement capabilities in April 2026. The available sources establish adoption and financing but do not disclose revenue figures.
Founders & Leadership
Funding History
Y Combinator
Surge
TEN13
Peak XV Partners
Recent News
Arintra announced that co-founder and CTO Preeti Bhargava was named to Becker’s 170 Women in Health IT to Know for 2026.
Arintra’s autonomous coding platform won the 2026 Pinnacle Award for AI Innovation in Healthcare, recognizing the company’s work in healthcare AI and autonomous medical coding.
Arintra launched a documentation-improvement capability designed to identify gaps in clinical documentation and support more complete medical coding. Media coverage also reported that the company had signed 13 enterprise deals at the end of 2025.
Arintra reported an A+ partnership rating in the KLAS Emerging Company Spotlight Report. Customers gave the company an overall performance score of 93 out of 100, compared with a 2026 Best in KLAS software average of 81.1.
Arintra highlighted its approach to autonomous medical-coding pilots in a podcast focused on achieving a 100% pilot success rate by demonstrating return on investment.
Arintra reported that customers reduced coding costs by nearly one-third, while the company achieved strong customer retention and 8x revenue growth. The announcement followed its August 2025 Series A and described plans to broaden revenue-cycle workflows.
Mercyhealth expanded its use of Arintra’s AI coding capabilities across 10 specialties. The reported results included more than 5% revenue uplift, over 64% reduction in pre-A/R days, and more than 43% fewer denials.
Yahoo Finance coverage described Arintra’s plans to use its new funding to expand coverage across medical specialties, improve clinical documentation, and strengthen denial analytics.
The Economic Times reported that Texas-based Arintra raised $21 million in Series A funding led by Peak XV Partners.
Arintra announced a $21 million Series A led by Peak XV Partners to expand beyond autonomous medical coding and develop broader healthcare revenue-assurance capabilities. The announcement cited Mercyhealth results including a 5.1% revenue increase and a 43% reduction in denials on automated claims.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
Arintra sells enterprise deployments of its AI revenue-cycle platform to health systems and physician groups. Its outcomes-first sales process begins with a proof-of-value phase before expanding into broader enterprise deployments; specific pricing is not publicly disclosed.
Products
Customers
Tech Stack
Similar Companies
Competitors
Key Investors
Peak XV Partners, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Spider Capital, Ten13